$LIFE - Is it time for Life ? MOEX:LIFE - Is it time for Life ?
Analyst Ratings are so good .... Momentum can keep up ?
Will see... Good Luck ....
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.84EUR
−45.65 MEUR
319.82 KEUR
67.09 M
About aTyr Pharma, Inc.
Sector
CEO
Sanjay S. Shukla
Headquarters
San Diego
Website
Employees (FY)
59
Founded
2005
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
$LIFE completed cup & handle pattern this week on the 4HPhase 3 trial completion coming up in August but it appears momentum is pulling this up well ahead of it.
$LIFE A New FrontierAhealthy immune system is like Goldilocks’s pudding where if it is too active, then the immune system attacks healthy tissue causing an autoimmune disease, while if it is not that active, then a simple cold could be fatal. The immune system has to be just right to combat diseases without harming hea
aTyr Pharma Announces FDA Orphan Drug DesignationLIFE: aTyr Pharma, Inc.
2022-04-13 08:00:00
aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis
Life rounding bottom with retest of support Round bottom with a breakout then retests of that support. I Will wait for a confirmation candle to see it holds the support
LIFE: Bullish Pennant (89%)Bullish Pennant, not confirmed yet.
If confirmed, could see a PT = 18.40$
Stay humble, have fun, make money!
Nice trades on LIFEscanner showed me LIFE with a high pre-market % value
my entry is a breakout of the 5 min bar.
long or short but onlyf if there is no resistance
tuesdays short had the target prior day high.
for long trade i trail the stop on a 2-3 bar trailing stop
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical TrLIFE: aTyr Pharma, Inc.
2021-09-13 07:30:00
aTyr Pharma Announces Positive Data from Phase 1b/2a Clinical Trial Demonstrating Consistent Dose Response for ATYR1923 in Pulmonary Sarcoidosis
LIFE / aTyr Pharma*investment opportunity - risky ~$40m market capital*
Happy with the risk?
Shown on the above 10-day chart price action has dropped 99% since May 2015 with a 1:14 reverse split in July 2019, price action is severely depressed.
A ‘incredible buy’ opportunity was illuminated in early 2018, however
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 471A is 1.63 EUR — it has decreased by 1.81% in the past 24 hours. Watch ATYR PHARMA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ATYR PHARMA INC stocks are traded under the ticker 471A.
471A stock has fallen by 15.10% compared to the previous week, the month change is a 10.14% rise, over the last year ATYR PHARMA INC has showed a 25.23% decrease.
We've gathered analysts' opinions on ATYR PHARMA INC future price: according to them, 471A price has a max estimate of 32.24 EUR and a min estimate of 14.74 EUR. Watch 471A chart and read a more detailed ATYR PHARMA INC stock forecast: see what analysts think of ATYR PHARMA INC and suggest that you do with its stocks.
471A reached its all-time high on Sep 23, 2021 with the price of 10.90 EUR, and its all-time low was 1.02 EUR and was reached on Nov 16, 2023. View more price dynamics on 471A chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
471A stock is 3.75% volatile and has beta coefficient of 1.48. Track ATYR PHARMA INC stock price on the chart and check out the list of the most volatile stocks — is ATYR PHARMA INC there?
Today ATYR PHARMA INC has the market capitalization of 114.43 M, it has increased by 5.81% over the last week.
Yes, you can track ATYR PHARMA INC financials in yearly and quarterly reports right on TradingView.
ATYR PHARMA INC is going to release the next earnings report on Aug 14, 2024. Keep track of upcoming events with our Earnings Calendar.
471A earnings for the last quarter are −0.21 EUR per share, whereas the estimation was −0.23 EUR resulting in a 8.00% surprise. The estimated earnings for the next quarter are −0.21 EUR per share. See more details about ATYR PHARMA INC earnings.
ATYR PHARMA INC revenue for the last quarter amounts to 217.79 K EUR despite the estimated figure of 33.98 K EUR. In the next quarter revenue is expected to reach 36.85 K EUR.
471A net income for the last quarter is −14.36 M EUR, while the quarter before that showed −13.37 M EUR of net income which accounts for −7.36% change. Track more ATYR PHARMA INC financial stats to get the full picture.
No, 471A doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 28, 2024, the company has 59.00 employees. See our rating of the largest employees — is ATYR PHARMA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ATYR PHARMA INC EBITDA is −51.91 M EUR, and current EBITDA margin is −14.78 K%. See more stats in ATYR PHARMA INC financial statements.
Like other stocks, 471A shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ATYR PHARMA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ATYR PHARMA INC technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ATYR PHARMA INC stock shows the sell signal. See more of ATYR PHARMA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.